Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like protein 16 (ARL16) is a member of the ARF family of small GTPases within the Ras superfamily[1][3]. It is an evolutionarily conserved protein found in virtually all ciliated eukaryotes, where it localizes mainly to cilia, basal bodies, and Golgi apparatus[1][2]. Its primary recognized function is the regulation of trafficking of specific proteins (including IFT140 and INPP5E) from the Golgi to the cilium, influencing cilia structure, composition, and signaling[1][2]. Loss of ARL16 impairs cilia formation, alters ciliary protein profiles, and affects key ciliary and signaling pathways such as Hedgehog signaling[1][2]. ARL16 also acts as a negative regulator of the RIG-I pathway, thereby modulating innate immune signaling through direct inhibition of RIG-I in a GTP-dependent manner[3]. No disease is directly caused by ARL16 mutations, and it is not currently a therapeutic target or biomarker, nor are there approved drugs acting through it. Its functional importance in ciliary protein sorting and immune regulation suggests a role in disorders of cilia or immunity, but this remains to be clarified by future research[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor-like protein 16 (ARL16).